TY - JOUR T1 - COVID-PCD – a participatory research study on the impact of COVID-19 in people with Primary Ciliary Dyskinesia JF - medRxiv DO - 10.1101/2020.11.11.20229922 SP - 2020.11.11.20229922 AU - Eva SL Pedersen AU - Eugénie NR Collaud AU - Rebeca Mozun AU - Cristina Ardura-Garcia AU - Yin Ting Lam AU - Amanda Harris AU - Jane S Lucas AU - Fiona Copeland AU - Michele Manion AU - Bernhard Rindlishbacher AU - Hansruedi Silberschmidt AU - COVID-PCD patient advisory group AU - Myrofora Goutaki AU - Claudia E Kuehni Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/12/2020.11.11.20229922.abstract N2 - Introduction COVID-PCD is a participatory study initiated by people with PCD who have an essential vote in all stages of the research from the design of the study to the recruitment of participants, and interpretation and communication of the study results. COVID-PCD aims to collect epidemiological data in real time from people with PCD throughout the pandemic to describe incidence of COVID-19, symptoms, and course of disease; identify risk factors for prognosis; and assess experiences, wishes, and needs.Methods The study is advertised through patient support groups and participants register online on the study website (www.covid19pcd.ispm.ch). The study invites persons of any age from anywhere in the world with a suspected or confirmed PCD. A baseline questionnaire assesses details on PCD diagnosis, habitual symptoms, and COVID-19 episodes that occurred before study entry. Afterwards, participants receive a weekly follow-up questionnaire with questions on incident SARS-CoV-2 infections, current symptoms, social contact behaviour, and physical activity. Occasional thematic questionnaires are sent out focusing on emerging questions of interest chosen by people with PCD. In case of hospitalisation, patients or family members are asked to obtain a hospital report. Results are continuously analysed and summaries put online.Conclusion The study started recruitment on April 30, 2020, and 556 people with PCD completed the baseline questionnaire by November 2, 2020. The COVID-PCD study is a participatory study that follows people with PCD during the COVID-19 pandemic, helps to empower affected persons, and serves as a platform for communication between patients, physicians, and researchers.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04602481Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04602481?cond=primary+ciliary+dyskinesia&draw=2&rank=2 Funding StatementThis research was funded by the Swiss National Foundation (SNF 320030B_192804/1); the PCD Foundation, United States; the Verein Kartagener Syndrom und Primaere Ciliaere Dyskinesie, Germany; and the PCD Family Support Group, UK. Study authors participate in the BEAT-PCD clinical research collaboration, supported by the European Respiratory Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Bern Cantonal Ethics Committee (Kantonale Ethikkomission Bern) has approved this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers who wish to use data should submit a concept sheet describing the planned analysis and send it to Prof. Claudia Kuehni (Claudia.kuehni@ispm.unibe.ch). The concept sheet will be discussed with the patient advisory group and if agreed, a partial dataset will be prepared by the research team. ER -